MetaCap

BioStem Technologies (BSEM) vs Estrella Immunopharma (ESLA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Estrella Immunopharma (ESLA) has outperformed BioStem Technologies (BSEM) over the past year, losing 78.9% versus a loss of 84.0%. Over five years, BSEM leads with a -55.9% price change compared with -96.8% for ESLA. Estrella Immunopharma is the larger company by market cap ($14.1 million vs $12.2 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BSEM-83.98%ESLA-78.88%
+116%+11%-94%
Nov 21, 20251 yearNov 20, 2026
BSEM-25.28%ESLA-96.76%
+2716%+1243%-231%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BSEM versus ESLA key metrics
MetricBSEMESLA
Share price$0.6351$0.321
Market cap$12.18M$14.11M
1-day change-10.23%-5.70%
YTD return-83.33%-79.42%
1-year return-83.98%-78.88%
5-year return-55.90%-96.78%
P/E ratio (TTM)0.72—
Forward P/E2.19—
EPS (TTM)$0.88$-0.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-13.06M
52-week high$8.40$2.27
52-week low$0.5347$0.24
Distance from 52-week high-92.44%-85.86%
Analyst consensusnonenone
Avg. price target upside+1002.19%+3638.32%
Average volume194.93K2.04M
Shares outstanding19.18M43.97M
Employees73—
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BioStem Technologies

BSEM stock →

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 73 employees

About Estrella Immunopharma

ESLA stock →

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

BSEM vs ESLA FAQ

Which is bigger, BioStem Technologies or Estrella Immunopharma?

Estrella Immunopharma (ESLA) is larger, with a market capitalization of $14.11M compared with $12.18M for BioStem Technologies (BSEM).

Which stock has performed better over the past year, BSEM or ESLA?

ESLA returned -78.88% over the past 12 months, compared with -83.98% for BSEM (price return, excluding dividends). Past performance does not predict future results.

Are BioStem Technologies and Estrella Immunopharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons